The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
To date, there are no approved treatments for vascular cognitive impairment (VCI) and the
main therapeutic efforts are aimed at controlling vascular risk factors for countering VCI
development or progression. Several studies have reported cholinergic deficits in brain and
cerebrospinal fluid of patients with VCI. The effect of choline alphoscerate in clinical
studies of Alzheimer's disease and VCI improved memory and attention impairments. The purpose
of our study is to determine effectiveness of choline alphoscerate vs placebo in improving
cognition in post-stroke patients with VCI-non dementia (VCI-ND).